Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 450

1.

Erratum: Author Correction: Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease.

Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C, Guzman NV, Hellman B, James B, Pal S, Stamford J, Steiger M, Stott RW, Teo J, Barker RA, Wang E, Bloem BR, van der Eijk M, Rochester L, Williams A.

NPJ Parkinsons Dis. 2017 Nov 13;3:32. doi: 10.1038/s41531-017-0034-0. eCollection 2017.

2.

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.

Barker RA, Parmar M, Studer L, Takahashi J.

Cell Stem Cell. 2017 Nov 2;21(5):569-573. doi: 10.1016/j.stem.2017.09.014.

PMID:
29100010
3.

11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.

Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P.

Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27183. [Epub ahead of print]

PMID:
29082547
4.

An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease.

Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J, Jones PS, Rowe JB, Rubinsztein DC, Barker RA.

J Neurol. 2017 Dec;264(12):2457-2463. doi: 10.1007/s00415-017-8647-0. Epub 2017 Oct 26.

5.

Associations between Lifestyle Factors and Parkinson's Disease in an Urban Sri Lankan Clinic Study.

Wijeyekoon R, Suriyakumara V, Gamage R, Fernando T, Jayasuriya A, Amarasinghe D, Gunasekara H, Sirisena D, Amaratunga D, Muthukuda C, Barker RA, Williams-Gray C, De Silva R.

Int Arch Med. 2017 Sep 15;10. pii: 246. doi: 10.3823/2516.

6.

Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned?

Drouin-Ouellet J, Pircs K, Barker RA, Jakobsson J, Parmar M.

Front Neurosci. 2017 Sep 28;11:530. doi: 10.3389/fnins.2017.00530. eCollection 2017. Review.

7.

Spatial structure normalises working memory performance in Parkinson's disease.

Fallon SJ, Bor D, Hampshire A, Barker RA, Owen AM.

Cortex. 2017 Nov;96:73-82. doi: 10.1016/j.cortex.2017.08.023. Epub 2017 Sep 1.

PMID:
28985531
8.

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely DM, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2017 Jul 13;7(1):5280. doi: 10.1038/s41598-017-05709-y.

9.

Parkinson disease: Defining PD subtypes - a step toward personalized management?

Williams-Gray CH, Barker RA.

Nat Rev Neurol. 2017 Aug;13(8):454-455. doi: 10.1038/nrneurol.2017.98. Epub 2017 Jul 7. No abstract available.

PMID:
28685759
10.

Normal aging and Parkinson's disease are associated with the functional decline of distinct frontal-striatal circuits.

Gruszka A, Hampshire A, Barker RA, Owen AM.

Cortex. 2017 Aug;93:178-192. doi: 10.1016/j.cortex.2017.05.020. Epub 2017 Jun 3.

11.

Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease.

Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C, Guzman NV, Hellman B, Ben James, Pal S, Stamford J, Steiger M, Stott RW, Teo J, Barker RA, Wang E, Bloem BR, van der Eijk M, Rochester L, Williams A.

NPJ Parkinsons Dis. 2017 Jan 9;3:2. doi: 10.1038/s41531-016-0003-z. eCollection 2017. Erratum in: NPJ Parkinsons Dis. 2017 Nov 13;3:32.

12.

REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways.

Drouin-Ouellet J, Lau S, Brattås PL, Rylander Ottosson D, Pircs K, Grassi DA, Collins LM, Vuono R, Andersson Sjöland A, Westergren-Thorsson G, Graff C, Minthon L, Toresson H, Barker RA, Jakobsson J, Parmar M.

EMBO Mol Med. 2017 Aug;9(8):1117-1131. doi: 10.15252/emmm.201607471.

13.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.

PMID:
28642124
14.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16.

PMID:
28629879
15.

Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD).

Kirkeby A, Parmar M, Barker RA.

Prog Brain Res. 2017;230:165-190. doi: 10.1016/bs.pbr.2016.11.011. Epub 2017 Feb 7.

PMID:
28552228
16.

Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis.

Garofalo S, Justicia A, Arrondo G, Ermakova AO, Ramachandra P, Tudor-Sfetea C, Robbins TW, Barker RA, Fletcher PC, Murray GK.

Front Neurol. 2017 Apr 24;8:156. doi: 10.3389/fneur.2017.00156. eCollection 2017.

17.

Neural grafting for Parkinson's disease: challenges and prospects.

Stoker TB, Blair NF, Barker RA.

Neural Regen Res. 2017 Mar;12(3):389-392. doi: 10.4103/1673-5374.202935. Review.

18.

Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases.

Malek N, Lawton MA, Grosset KA, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG; PRoBaND clinical consortium.

Parkinsonism Relat Disord. 2017 Jul;40:40-46. doi: 10.1016/j.parkreldis.2017.04.006. Epub 2017 Apr 12.

19.

Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.

Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Mollenhauer B, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O'Brien JT.

Neurobiol Aging. 2017 Jul;55:78-90. doi: 10.1016/j.neurobiolaging.2017.03.012. Epub 2017 Mar 16.

20.

A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS.

Bao L, Al-Assar O, Drynan LF, Arends MJ, Tyers P, Barker RA, Rabbitts TH.

Sci Rep. 2017 Mar 21;7:44899. doi: 10.1038/srep44899.

Supplemental Content

Loading ...
Support Center